- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06. | Filament Health Enters Into Exclusive License Agreement With University Of Alabama At Birmingham For Data From A Clinical Trial Of Psilocybin For The Treatment Of Cocaine Use Disorder | 2 | CNW | ||
| 11.06. | Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder | 1 | CNW | ||
| 28.05. | Filament Health Announces Transition From Otcqb To Otc Pink Limited | 3 | CNW | ||
| 22.05. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.05.2025 | 632 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 22.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.05.2025.ISIN NameCA31685W1068 FILAMENT... ► Artikel lesen | |
| 22.05. | XFRA 7QS: AUSSETZUNG/SUSPENSION | 200 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFILAMENT HEALTH... ► Artikel lesen | |
| FILAMENT HEALTH Aktie jetzt für 0€ handeln | |||||
| 20.05. | Filament Health Corp: Filament shares to delist from Cboe Canada May 21 | 1 | Stockwatch | ||
| 19.05. | Filament Health Corp.: Filament Health Announces Voluntary Delisting From Cboe Canada | 119 | PR Newswire | VANCOUVER, BC, May 19, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 09.05. | Filament Health reports Q1 results | 1 | Seeking Alpha | ||
| 09.05. | Filament Health Corp.: Filament Health Announces First Quarter 2025 Financial Results And Operational Highlights | 52 | PR Newswire | VANCOUVER, BC, May 8, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 09.04. | Filament Health Corp: Filament receives U.S. FDA OK for PEX010 study | 1 | Stockwatch | ||
| 09.04. | Filament Health Announces Fda Authorization Of Phase 2 Clinical Trial Studying Pex010, The Company's Botanical Psilocybin Drug Candidate, In Opioid Use Disorder | 2 | CNW | ||
| 04.04. | Filament Health to raise C$0.9M, delist from Cboe Canada | 1 | Seeking Alpha | ||
| 04.04. | Filament Health Corp: Filament Health arranges $900,000 private placement | 2 | Stockwatch | ||
| 04.04. | Filament Health Corp.: Filament Health Announces Private Placement And Intention To Voluntarily Delist From Cboe Canada | 126 | PR Newswire | Financing driven by existing investor Negev and Filament's Board of Directors
Company also announces intention to voluntarily delist from Cboe Canada
VANCOUVER... ► Artikel lesen | |
| 01.04. | Filament Health Corp.: Filament Health Reports Q4 And Year End 2024 Financial Results And Operational Highlights | 84 | PR Newswire | VANCOUVER, BC, April 1, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 01.04. | Filament Health reports FY results | 1 | Seeking Alpha | ||
| 17.03. | Filament Health Corp: Filament Health talks PEX010 safety data | 1 | Stockwatch | ||
| 17.03. | Filament Health Corp.: Filament Health Announces Positive Data From Phase 2 Study Of Pex010 In Patients With Alcohol Use Disorder | 76 | PR Newswire | Open-label study at Psychiatric Centre Copenhagen found that alcohol consumption significantly decreased amongst participants dosed with Filament's botanical psilocybin... ► Artikel lesen | |
| 06.02. | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference | 455 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as... ► Artikel lesen | |
| 22.01. | Filament Health Corp: Filament Health ships PEX010 to UW-Madison | 1 | Stockwatch |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,195 | +0,56 % | Übernahmefieber! BioTech und Künstliche Intelligenz beflügelt Evotec, NetraMark Holdings, NovoNordisk und Bayer | Derzeit erlebt der Biotech-Sektor eine spannende Transformation: Denn Big Data und Künstliche Intelligenz verändern in rasanter Art und Weise, wie neue Medikamente entdeckt, entwickelt und getestet... ► Artikel lesen | |
| AURORA CANNABIS | 3,880 | 0,00 % | Aurora Cannabis Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| CANOPY GROWTH | 1,120 | +0,90 % | Canopy Growth Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| TILRAY BRANDS | 0,428 | +0,59 % | Here's why the Tilray Brands stock price has imploded | ||
| INNOCAN PHARMA | 0,136 | -0,37 % | Breaking News: Treibstoff für den Turnaround-Turbo?! | ||
| CRONOS GROUP | 1,741 | 0,00 % | Cronos Group Inc: Cronos Group expands distribution with Peace Naturals | ||
| SYNBIOTIC | 3,185 | +1,27 % | SYNBIOTIC SE: Update von der mwb-Konferenz: Diversifiziertes Geschäftsmodell gewinnt an Dynamik; mwb research empfiehlt KAUFEN | Auf der mwb research Health Care Conference bekräftigten CEO Daniel Kruse und sein Team den strategischen Fokus von SYNBIOTIC auf ein plattformbasiertes Buy-and-Build-Modell in wachstumsstarken Cannabis-... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 4,634 | +1,53 % | Green Thumb Industries Inc: Green Thumb to release Q2 2025 financial results Aug. 6 | ||
| CHRISTINA LAKE CANNABIS | 0,030 | -0,67 % | Christina Lake Cannabis Corp: Christina Lake files fiscal 2025 results | ||
| AXSOME THERAPEUTICS | 89,34 | +0,52 % | Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating | ||
| JAGUAR HEALTH | 2,560 | 0,00 % | Jaguar Health, Inc.: Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient | As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 91,94 | -0,07 % | EC approves Jazz Pharmaceuticals' Ziihera for biliary tract cancer | ||
| TRULIEVE CANNABIS | 3,264 | -2,91 % | Trulieve Cannabis Corp: Trulieve files registration statement on Form S-3 | ||
| CORBUS PHARMACEUTICALS | 6,350 | -1,55 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals... ► Artikel lesen | |
| CANNOVUM CANNABIS | 0,250 | 0,00 % | EQS-News: Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich | EQS-News: Cannovum Cannabis AG
/ Schlagwort(e): Strategische Unternehmensentscheidung/Sonstiges
Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich... ► Artikel lesen |
Das Unternehmen FILAMENT HEALTH CORP kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FILAMENT HEALTH CORP finden Sie auf Wallstreet Online.